EuroEyes International Eye Clinic Limited (1846) AI Stock Analysis

• Market Cap: HK$959.32M
• Dividend Yield: 2.84%
• Average Volume (3M): 115.27K
• Price to Earnings (P/E): 12.0
• Beta (1Y): 0.25
• Revenue Growth: 0.20%
• EPS Growth: -36.95%
• Country: HK
• Employees: 322
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Care Facilities
• EPS (TTM): 0.12
• Shares Outstanding: 320,706,000
• 10 Day Avg. Volume: 19,400
• 30 Day Avg. Volume: 115,268
• PEG Ratio: -0.53
• Price to Book (P/B): 0.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ―

EuroEyes International Eye Clinic Limited demonstrates strong financial foundations with robust revenue growth and low leverage. However, challenges are present due to declining profit margins and lack of cash flow transparency. Technical analysis suggests bearish trends and momentum, while valuation metrics indicate the stock is fairly priced with a reasonable dividend yield. These factors combined result in a moderate overall score, with emphasis on improving cash flow and cost management being critical for future performance.

EuroEyes International Eye Clinic Limited Business Overview & Revenue Model

Company Description

EuroEyes International Eye Clinic Limited (1846) is a leading provider of vision correction services in Europe and China. The company specializes in offering a wide range of refractive surgery and eye care solutions, including laser vision correction, refractive lens exchange, and cataract surgeries. With a strong presence in Germany, Denmark, and China, EuroEyes operates state-of-the-art clinics and employs experienced ophthalmologists to deliver high-quality eye care services to its patients.

How the Company Makes Money

EuroEyes International Eye Clinic Limited primarily generates revenue through the provision of surgical eye care services. The company's key revenue streams include fees for laser vision correction procedures, such as LASIK and SMILE, and other advanced refractive surgeries like refractive lens exchange and cataract surgeries. EuroEyes charges patients directly for these procedures, and the revenue is further supported by consultations, pre-operative assessments, and post-operative care. Additionally, the company benefits from its strategic locations in high-demand markets across Europe and China and leverages its reputation for quality and innovation in ophthalmic services to attract a steady flow of patients. Partnerships with medical device manufacturers and suppliers also contribute to the company's ability to provide cutting-edge technology and maintain competitive pricing.

EuroEyes International Eye Clinic Limited Financial Statement Overview

Summary

EuroEyes International Eye Clinic Limited shows a solid financial position with strong revenue growth and low leverage. However, recent declines in profit margins and missing cash flow data may pose challenges. The Balance Sheet remains robust, providing support during potential financial fluctuations. Continued focus on improving cost efficiencies and cash flow management will be crucial to sustain its financial health.

Income Statement

The company shows a consistent revenue growth trajectory, with revenue increasing from HK$427.2M in 2019 to HK$715.7M in 2024, indicating strong demand for its services. The Gross Profit Margin has slightly decreased from 47.8% in 2023 to 40.1% in 2024, suggesting some pressure on cost management. The Net Profit Margin also decreased from 18.4% to 11.5%. Despite these declines, EBIT and EBITDA margins remained reasonably robust, reflecting effective operational management.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of roughly 68.3% in 2024, indicating financial stability. The Debt-to-Equity Ratio is relatively low at 0.29, suggesting low leverage and reduced financial risk. However, a slight decline in Stockholders' Equity from 2023 to 2024 could be a potential concern if it continues.

Cash Flow

The lack of reported Operating Cash Flow and Free Cash Flow in 2024 raises concerns about the company's cash generation capabilities. In prior years, there was positive Free Cash Flow, indicating previously healthy operations. The absence of cash flow data for 2024 could signal potential operational or financial challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
715.68M	714.29M	610.29M	632.93M	473.82M
	Gross Profit
286.59M	335.52M	270.84M	312.55M	214.10M
	EBIT
115.78M	193.51M	132.81M	191.26M	111.06M
	EBITDA
141.89M	292.10M	220.44M	278.80M	173.62M
	Net Income Common Stockholders
82.28M	131.24M	89.47M	133.56M	65.58M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
680.67M	720.38M	779.57M	861.58M	761.89M
	Total Assets
1.60B	1.75B	1.54B	1.37B	1.31B
	Total Debt
319.29M	384.26M	290.41M	221.48M	239.55M
	Net Debt
-333.95M	-335.95M	-489.16M	-624.16M	-522.35M
	Total Liabilities
473.72M	588.09M	497.95M	328.55M	324.57M
	Stockholders Equity
1.09B	1.13B	1.01B	1.01B	953.29M
Cash Flow		Free Cash Flow
0.00	102.30M	152.46M	228.71M	40.12M
	Operating Cash Flow
0.00	191.85M	208.76M	273.26M	78.46M
	Investing Cash Flow
0.00	-180.28M	-131.81M	-59.90M	-38.13M
	Financing Cash Flow
0.00	-102.76M	-102.22M	-69.18M	-116.37M

EuroEyes International Eye Clinic Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Neutral. The current price of 3 is above the 20-day moving average (MA) of 2.93, above the 50-day MA of 2.92, and below the 200-day MA of 3.70, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.26 is Neutral, neither overbought nor oversold. The STOCH value of 31.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1846.

EuroEyes International Eye Clinic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6869	74 Outperform	$20.95B	15.06	6.68%	3.41%	0.24%	-31.74%
3613	68 Neutral	$7.36B	14.71	12.58%	6.90%	5.69%	-7.43%
1846	61 Neutral	HK$959.32M	12.03	7.39%	2.84%	0.20%	-36.95%
1518	59 Neutral	HK$571.08M	11.01	8.82%	1.89%	-10.82%	-43.85%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
1529	44 Neutral	HK$270.17M	―	-18.43%	―	88.08%	17.57%
1312	36 Underperform	HK$156.20M	―	-7.42%	―	10.93%	-159.62%

EuroEyes International Eye Clinic Limited Corporate Events

EuroEyes Announces 2025 Annual General Meeting Agenda

EuroEyes International Eye Clinic Limited has announced its upcoming Annual General Meeting scheduled for June 6, 2025, in Hong Kong. Key agenda items include the adoption of financial statements, approval of a final dividend, re-election of directors, re-appointment of auditors, and granting of mandates to issue and repurchase shares. These decisions are poised to impact the company’s governance and financial strategies, potentially affecting shareholder value and market positioning.

EuroEyes Announces Change of Company Website

EuroEyes International Eye Clinic Limited has announced a change in its company website address from ‘www.euroeyes.hk’ to ‘www.euroeyes.com’, effective from April 23, 2025. This change will ensure that all future announcements and documents submitted to the Hong Kong Stock Exchange will be accessible on the new website, potentially enhancing the company’s online presence and accessibility for stakeholders.

EuroEyes Announces Final Dividend for 2024

EuroEyes International Eye Clinic Limited has announced a final ordinary cash dividend of HKD 0.0297 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders, with the payment scheduled for June 27, 2025.

EuroEyes Reports Decline in Profit Despite Revenue Growth

EuroEyes International Eye Clinic Limited reported its annual results for the year ended December 31, 2024, showing a slight increase in revenue but a significant decline in profit. The company’s gross profit and net profit after tax decreased by 14.6% and 36.7%, respectively, compared to the previous year. The adjusted financial measures, which exclude non-cash and one-off items, also showed declines. These results reflect the financial impact of pre-operating expenses for new clinics and other non-recurring costs, indicating challenges in maintaining profitability amid expansion efforts.

EuroEyes Issues Profit Alert Amid Challenging Market Conditions

EuroEyes International Eye Clinic Limited has issued a profit alert, indicating a decrease in profit and EBITDA for the year ended December 31, 2024, compared to the previous year. The decline is attributed to increased costs from new clinics and challenging economic conditions affecting demand in Europe and China. Despite these challenges, the company maintained a strong EBITDA margin, particularly in Germany.

EuroEyes Schedules Board Meeting to Review Annual Results and Dividend

EuroEyes International Eye Clinic Limited has announced a board meeting scheduled for March 31, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend, which could impact shareholder returns and reflect the company’s financial health and strategic direction.